Protara Therapeutics, INC Form 4 insider transactions

Opaleye Management Inc. reports selling shares of Protara Therapeutics (TARA) on June 27 and 28, 2024, resulting in a decreased beneficial ownership.

Opaleye Management Inc., a 10% owner of Protara Therapeutics, sold shares of the company's common stock on June 25, 2024.

Director Barry P. Flannelly acquired 10,000 stock options in Protara Therapeutics, Inc. on June 7, 2024.

Director Cynthia Smith acquired 10,000 stock options in Protara Therapeutics on June 7, 2024.

Michael Edward Solomon, a director of Protara Therapeutics, acquired 10,000 stock options on June 7, 2024.

Director Gregory SARGENT acquired 10,000 stock options in Protara Therapeutics, Inc. on June 7, 2024, at an exercise price of $2.67.

Director Richard S. Levy acquired stock options for 10,000 shares of Protara Therapeutics, Inc. on June 7, 2024.

Director Jane Huang acquired 10,000 stock options in Protara Therapeutics, Inc. on June 7, 2024.

Director Roger Garceau acquired stock options for 10,000 shares of Protara Therapeutics, Inc. at an exercise price of $2.67 on June 7, 2024.

Director Luke M. Beshar acquired 10,000 stock options in Protara Therapeutics, Inc. on June 7, 2024.

Opaleye Management Inc. reports the purchase and disposal of Protara Therapeutics, Inc. shares through a managed account.

Opaleye Management Inc. reports the sale of Protara Therapeutics shares held by Opaleye, L.P. and a managed account.

Opaleye Management Inc. reports the sale of Protara Therapeutics shares held by Opaleye, L.P. and a managed account.

Opaleye Management Inc. reports the sale of Protara Therapeutics shares over two days, reducing its beneficial ownership.